Trial Profile

Pivotal study of ATRS-1902 for treatment of adrenal crisis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydrocortisone (Primary)
Indications Adrenal insufficiency
Focus Registrational; Therapeutic Use
Sponsors Antares Pharma

Most Recent Events

18 Jan 2022 drug route and patient gender assumed.
18 Jan 2022 New trial record
11 Jan 2022 According to an Antares Pharma media release, the company expect to file the 505(b)(2) NDA with the FDA by the end of 2022 assuming the successful completion of the pivotal study and an additional human factor study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com